<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">scbmt</journal-id><journal-title-group><journal-title xml:lang="ru">БИОМЕДИЦИНА</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Biomed</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-5982</issn><issn pub-type="epub">2713-0428</issn><publisher><publisher-name>Scientific center of biomedical technologies of Federal Medical and Biological Agency</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">scbmt-662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Особенности доклинических токсикологических
исследований лекарственных средств, созданных
на основе биотехнологии</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гуськова</surname><given-names>Т. А.</given-names></name></name-alternatives><email xlink:type="simple">tagus@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хаитов</surname><given-names>Р. М.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГБУ «ГНЦ Институт иммунологии» ФМБА России, Москва</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2020</year></pub-date><volume>1</volume><issue>3</issue><fpage>76</fpage><lpage>78</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гуськова Т.А., Хаитов Р.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Гуськова Т.А., Хаитов Р.М.</copyright-holder><copyright-holder xml:lang="en">Гуськова Т.А., Хаитов Р.М.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.scbmt.ru/jour/article/view/662">https://journal.scbmt.ru/jour/article/view/662</self-uri><abstract><p>Традиционные подходы к изучению токсичности биофармпрепаратов могут быть неприемлемы в
связи с уникальностью и разнообразием структурных и биологических свойств последних, которые
могут включать видовую специфику, иммуногенность и др. В этих случаях необходимо выявить об-
ласти несоответствия и оценить степень их важности по отношению к общей оценке безопасности.
Учитывая видовую специфику многих биофармпрепаратов, особое значение при изучении их токсич-
ности имеет выбор животных подходящего вида.
That the traditional approaches to the toxicological studies of biopharmaceuticals are unsuitable because
of their unique and diversified structural and biological properties, which can include the species-related
properties, immunogenic, etc. In such situation the scope of variance shall be identified and its importance
for general safety evaluation shall be considered. Bearing in mind the species-related characteristics of many
biopharmaceuticals, the emphasis shall be made on the selection of suitable animal species for toxicological
studies.</p></abstract><kwd-group xml:lang="ru"><kwd>биофармпрепараты</kwd><kwd>токсичность</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гуськова Т.А. // Токсикология ле- карственных средств. М.: МДВ. 2008. С.155-179.</mixed-citation><mixed-citation xml:lang="en">Гуськова Т.А. // Токсикология ле- карственных средств. М.: МДВ. 2008. С.155-179.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">ICH Guideline S4: Duration of chronic toxicity testing in animals (rodent and non-rodent toxicity testing) (CPMP/ ICH/300/95).</mixed-citation><mixed-citation xml:lang="en">ICH Guideline S4: Duration of chronic toxicity testing in animals (rodent and non-rodent toxicity testing) (CPMP/ ICH/300/95).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Addis A., Sharabi s., Bonati M. // Risk classification systems for drug use during pregnancy. Drug Safety. 2000. V. 3. C. 245-253.</mixed-citation><mixed-citation xml:lang="en">Addis A., Sharabi s., Bonati M. // Risk classification systems for drug use during pregnancy. Drug Safety. 2000. V. 3. C. 245-253.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
